Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers

Vaccine

Volumn 33, Issue 29, 2015, Pages 3322-3330

  Findlow, Jamie ^a   Bai, Xilian ^a   Findlow, Helen ^a   Newton, Emma ^a   Kaczmarski, Ed ^a   Miller, Elizabeth ^b   Borrow, Ray ^a,c  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

4CMenB; ACWY CRM; Laboratory workers; Meningococcal; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; 4CMENB VACCINE; BACTERIUM ANTIBODY; MENACWY-CRM VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; MALE; MEDICAL STAFF; MYALGIA; NAUSEA AND VOMITING; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; OPEN STUDY; PAIN; PRIORITY JOURNAL; SERUM BACTERICIDAL ANTIBODY ASSAY; VACCINATION; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GREAT BRITAIN; HEALTH CARE PERSONNEL; IMMUNOLOGY; LABORATORY; MIDDLE AGED; NORMAL HUMAN; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SERUM BACTERICIDAL ACTIVITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GREAT BRITAIN; HEALTH PERSONNEL; HEALTHY VOLUNTEERS; HUMANS; LABORATORIES; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; YOUNG ADULT;

EID: 84931562744     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.027     Document Type: Article

References (41)

1. Bai X., Findlow J., Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011, 11:969-985.
2. Borrow R., Findlow J., Gray S., Taylor S., Kaczmarski E. Safe laboratory handling of Neisseria meningitidis. J Infect 2014, 65:305-312.
3. Boutet R., Stuart J.M., Kaczmarski E.B., Gray S.J., Jones D.M., Andrews N. Risk of laboratory-acquired meningococcal disease. J Hosp Infect 2001, 49:282-284.
4. Pace D. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults. Future Microbiol 2010, 5:1629-1640.
5. Martin N.G., Snape M.D. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn. Expert Rev Vaccines 2013, 12:837-858.
6. Abio A., Neal K.R., Beck C.R. An epidemiological review of changes in meningococcal biology during the last 100 years. Pathog Glob Health 2013, 107:373-380.
7. Richmond P., Kaczmarski E., Borrow R., Findlow J., Clark S., McCann R., et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000, 181:761-764.
8. Granoff D.M., Gupta R.K., Belshe R.B., Anderson E.L. Induction of immunological refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998, 178:870-874.
9. Findlow H., Sow S., Borrow R., Tapia M., Haidara F.C., Akinsola A.K., et al. Meningococcal group C and W135 immunological hyporesponsiveness in African toddlers. Clin Vaccine Immunol 2011, 18:1492-1496.
10. Jokhdar H., Borrow R., Sultan A., Adi M., Riley C., Fuller E., et al. Immunological hyporesponsiveness to group C but not group A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol 2004, 11:83-88.
11. Lal G., Balmer P., Joseph H., Dawson M., Borrow R. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol 2004, 11:272-279.
12. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B.J., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. J Clin Microbiol 1997, 4:156-167. The Multilaboratory Study Group.
13. World Health Organization. Requirements for meningococcal polysaccharide vaccine. World Health Organisation Technical Series No. 594. Geneva: WHO; 1976.
14. Borrow R., Aaberge I.S., Santos G.F., Eudey T.L., Oster P., Glennie A., et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diag Lab Immunol 2005, 12:970-976.
15. Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine using efficacy estimates from post-licensure surveillance in England. Clin Diag Lab Immunol 2003, 10:780-786.
16. Borrow R., Andrews N., Goldblatt D., Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: a re-evaluation of correlates of protection. Infect Immun 2001, 69:1568-1573.
17. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus: I. The role of humoral antibodies. J Exp Med 1969, 129:1307-1326.
18. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus: II. Development of natural immunity. J Exp Med 1969, 129:1327-1348.
19. Makela P.H., Kayhty H., Weckstrom P., Sivonen A., Renkonen O.V. Effect of group-A meningococcal vaccine in Army recruits in Finland. Lancet 1975, 2:883-886.
20. Findlow H., Borrow R. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT. Adv Ther 2013, 30:431-458.
21. Department of Health. Immunisation against infectious disease-'The Green Book'. (2006). http://immunisation.dh.gov.uk/category/the-green-book/.
22. Miller E., Salisbury D., Ramsay M. Planning registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001, 20(Supplement 1):S58-S67.
23. Findlow J., Taylor S., Aase A., Horton R., Heyderman R., Southern J., et al. Comparison and correlation of Neisseria meningitidis serogroup B immunologic assays and human antibody responses following three doses of the 'Norwegian' meningococcal outer membrane vesicle vaccine, MenBvac. Infect Immun 2006, 74:4557-4565.
24. Findlow J., Findlow H., Frankland S., Holland A., Holme D., Newton E., et al. Evaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine. JOMT 2014, 9:26.
25. Ishola D.A., Borrow R., Findlow H., Findlow J., Trotter C., Ramsay M.E. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol 2012, 19:1126-1130.
26. Trotter C., Findlow J., Balmer P., Holland A., Barchha R., Hamer N., et al. Seroprevalance of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol 2007, 14:863-868.
27. Borrow R., Southern J., Andrews N., Peake N., Rahim R., Acuna M., et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls. Vaccine 2001, 19:3043-3050.
28. Southern J., Deane S., Ashton L., Borrow R., Goldblatt D., Andrews N., et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 2004, 11:1100-1104.
29. Brunelli B., Del Tordello E., Palumbo E., Biolchi A., Bambini S., Comanducci M., et al. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine 2011, 29:1072-1081.
30. Commanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002, 195:1445-1454.
31. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, 107:19490-19495.
32. Kimura A., Toneatto D., Kleinschmidt A., Wang H., Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011, 18:483-486.
33. Alberer M., Burchard G., Jelinek T., Reisinger E.C., Meyer S., Forleo-Neto E., et al. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults. J Travel Med 2014, 22:105-114.
34. Alberer M., Burchard G., Jelinek T., Reisinger E.C., Beran J., Hlavata L.C., et al. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults. J Travel Med 2014, 22:48-56.
35. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicentre, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51:1127-1137.
36. Snape M.D., Dawson T., Oster P., Evans A., John T.M., Ohene-Kena B., et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life- a randomized comparative trial. Pediatr Infect Dis J 2010, 29:71-79.
37. McQuaid F., Snape M.D., John T.M., Kelly S., Robinson H., Houlden J., et al. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. PIDJ 2014, 33:760-766.
38. Santolayla M.E., O'Ryan M.L., Valenzuela M.T., Prado V., Vergara R., Munoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in Healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:614-624.
39. Read R.C., Baxter D., Chadwick D.R., Faust S.N., Finn A., Gordon S.B., et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014, 384:2123-2131.
40. Prymula R., Esposito S., Zuccotti G.V., Xia F., Toneatto D., Kohl I., et al. A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother 2014, 10:1993-2004.
41. ClinicalTrials.gov identifier: NCT01272180. www.clinicaltrials.gov (accessed 09.01.2015).